New genomic test spares patients chemotherapy with no adverse effect on survival
Testing a breast cancer tumour for its genomic signature can help identify which patients will need adjuvant systemic therapy (additional chemotherapy) after surgery, and spare its use in those for whom it is not necessary, ...
Mar 22, 2012
0
0